Enrolling By InvitationNCT07074704
tACS to Improve Negative Symptoms & Cognition in Long-term Hospitalized Schizophrenia Patients.
Device studyAges 18–65China
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- ShanghaiSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 11, 2025
- Recruitment status
- Enrolling By Invitation
- Enrollment listed in the registry
- 60
- Sponsor
- Tongji University
- Sponsor type
- University
- Study type
- Device
- Intervention type
- DEVICE
- Study phase
- Not clearly listed
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07074704
- Official title
Show the full official title
Transcranial Alternating Current Stimulation (tACS) as an Augmentation Treatment for Negative Symptoms and Cognitive Deficits in Long-term Hospitalized Schizophrenia Patients
Recruitment & locations
By invitationThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Shanghai
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Tongji University, a university.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as enrolling by invitation.
Want to explore more studies?
Explore studiesRelated studies
A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia
Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms
